Robotic Surgery in Gynaecologic Oncology

Robotic surgery in gynaecologic oncology is cancer surgery of the uterus, cervix and ovaries performed through small incisions with a surgeon-controlled robotic system. For Dr. Alka Dahiya, Senior Consultant, Gynaecological Surgical Oncology, BLK-Max Super Speciality Hospital, New Delhi, India, it lowers blood loss, pain and conversion to open surgery, but only in carefully selected patients whose oncological outcome is never compromised.

Her position is deliberately two-sided. Surgery as a whole is moving towards minimally invasive techniques, and gynaecology and gynaecologic oncology are moving with it in a big way. Yet, in her words, robotics is not a blanket rule applied to every patient. The rest of this guide sets out what the platform is, where it adds value, what it still costs, how surgeons learn it and where it is heading. Two companion articles go deeper: one on patient selection and containment rules for robotic cancer surgery, and one on four operated cases and the outcomes data behind them.

History of robotic surgery: from FDA approval to radical cancer surgery

The US Food and Drug Administration approved the first robotic surgical system, the da Vinci, in 2000, and cleared it for gynaecological surgery in 2005. Since then the platform has moved well beyond simple hysterectomy. Dr. Dahiya lists radical hysterectomy, lymphadenectomy (removal of lymph nodes to stage or treat a cancer) and cytoreductive surgery (removal of as much visible tumour as possible) among its oncological applications. Outside gynaecology, robotic surgery is increasingly used in urology, surgical oncology and general surgery.

The system she uses at BLK-Max is the da Vinci Surgical System, which she regards as offering numerous advantages over both conventional laparoscopic surgery and conventional open surgery.

The robotic platform: vision cart, patient cart and console

A robotic surgical system has three connected components:

1. The vision cart, which carries the camera system and the screen on which the operating team watches the surgery.
2. The patient-side cart, which carries the robotic arms. These are docked to ports placed in the patient's abdomen.
3. The surgeon console, where the surgeon sits, away from the table, and controls the camera and instruments.

The surgeon's hand movements at the console are translated by the system into movements of the instruments inside the patient. How the da Vinci system works in gynaecological surgery, instrument by instrument, is covered in Dr. Deepika Aggarwal's article on the da Vinci robot. A bedside assistant stays at the table to help with docking and undocking the arms, a role Dr. Dahiya describes as important for any surgeon starting out on the robot.

Advantages of robotic surgery in gynaecologic oncology

In Dr. Dahiya's account, the advantages of robotic surgery in gynaecologic oncology are better vision, more dexterous instruments, better ergonomics, faster recovery and fewer conversions to open surgery. She attributes the rapid adoption of robotics to these concrete gains.

• Three-dimensional vision. The robotic camera gives a 3D, magnified view, against the 2D image of standard laparoscopy.
• Wristed instruments. Robotic instruments offer seven degrees of freedom, against four with straight laparoscopic instruments. A degree of freedom is an independent direction of movement; the extra ones come from a wrist at the instrument tip that bends and rotates much like a human wrist.
• Ergonomics. The surgeon sits comfortably at the console rather than standing over the table with arms raised, so fatigue is lower and, in her view, performance is better.
• Recovery. Compared with open and laparoscopic surgery, she reports less blood loss, less post-operative pain and a faster recovery.
• Fewer conversions. Laparoscopic operations sometimes have to be converted to open surgery when the surgeon cannot navigate safely, particularly in extreme obesity or after sudden bleeding. In her experience those conversion rates are lower with the robot.
• Precision in cancer work. She describes the technology as very precise, with high dexterity, when performing oncological surgery.

She also cites published studies reporting a lower complication rate than laparoscopic or open surgery, and a higher lymph node yield than laparoscopy, particularly in cancer cytoreductive surgery. Lymph node yield matters because the number of nodes removed and examined underpins accurate staging.

Cost is the counterweight. A robotic operation costs more than a laparoscopic one, but Dr. Dahiya argues that once hospital stay and recovery period are counted, the overall investment comes out almost as good.

Benign indications: complex hysterectomy, endometriosis and cystectomy

Many of the robot's advantages show first in difficult benign surgery, and Dr. Dahiya uses it selectively there.

• Complex hysterectomy. She reaches for the robot when she anticipates a difficult hysterectomy: a patient with several previous operations, such as caesarean sections (LSCS) or laparotomies, in whom she expects dense adhesions.
• Severe endometriosis. Endometriosis is tissue similar to the lining of the uterus growing outside it, which can fuse the pelvic organs together and obliterate the normal surgical planes. She describes the robot here as "a pure bliss": the vision and precision let the surgeon remove endometriotic tissue completely, including deposits outside the ovaries and fallopian tubes.
• Ovarian cystectomy. When a cyst is removed and the ovary kept, she reports that preservation of ovarian tissue, measured by anti-Müllerian hormone (AMH, a blood marker of the remaining egg reserve), is much better after robotic cystectomy than after laparoscopic cystectomy.
• Other procedures. Tubal reversal, vaginoplasty, cerclage (a stitch that supports the cervix in pregnancy) and prolapse repair can all be performed robotically.

Robotic surgery in benign gynaecology has its own pillar on this site, from Dr. Deepika Aggarwal's masterclass on robotics in benign gynaecology. This series stays with the cancer surgeon's perspective.

Robotic surgery for gynaecological cancer: the rule that overrides everything

When the disease is malignant, Dr. Dahiya's first principle is that the oncological outcome cannot be compromised: not the recurrence rate, not the surgical margins, not the lymph node yield. At her centre the robot is used for pre-invasive lesions of the cervix, early-stage cervical and endometrial cancer, small ovarian masses, interval cytoreductive surgery for ovarian cancer after chemotherapy, and exenteration procedures for central recurrences of cervical cancer. Each of these comes with its own selection criteria and containment rules, which are set out in full in the companion article on patient selection. Dr. Dahiya's institutional series of 251 robotic operations and an annual audit of her own practice both point the same way, and the figures, with four of her operated cases, are in the companion article on cases and outcomes.

Cost and limitations of robotic gynaecological cancer surgery

In Dr. Dahiya's assessment, the main limitations of robotic gynaecological cancer surgery are cost, longer operating time and the training it demands, and she is direct that they are real.

Cost and insurance. Robotic surgery is still not covered by many insurance companies or government panels, which keeps rates high. She expects costs to fall over time as the technology is incorporated more widely. Asked during the session for a typical figure, she put the cost of robotic surgery for endometriosis at 4 to 5 lakh rupees, with the exact figure depending on the operation: whether the uterus is removed, or only a cystectomy is performed. Indicative costs for radical hysterectomy are on the radical hysterectomy cost page.

Operating time. Operations take somewhat longer, largely because of docking and undocking the robotic arms.

Training and volume. Training still has to expand in a big way. As more surgeons are trained and volumes rise, she expects rates to come down and expertise to grow.

The cost of a wrong decision. In oncology, an inadvertent injury, an inadvertent spillage of tumour or a wrong decision in cervical cancer or an ovarian mass can, in her words, land both the patient and the surgeon in trouble. Careful selection of surgical candidates is, for her, the precondition for using the technology at all.

Training and fellowships in robotic gynaecologic oncology

Dr. Dahiya's view is that a competent open surgeon can move directly to robotics without first mastering laparoscopy. Many surgeons, including herself, find robotics easier to learn than laparoscopy; prior minimally invasive exposure helps but is not a prerequisite.

She described a structured pathway run with the support of Intuitive:

1. Level 1: simulation. The surgeon practises on a simulator how to operate on a live patient, and is certified.
2. Level 2. Reached once the surgeon has completed at least 30 to 50 procedures, independently or with help.
3. Advanced training follows.

She has performed around 300 robotic operations herself and began to feel confident after around 50. Her estimate is that a surgeon who commits to robotics becomes confident within about a year. In her closing summary she cited the common rule of thumb that a surgeon who has performed at least 25 to 50 hysterectomies is "good to go". Dedicated one-year fellowships in robotic surgical oncology and robotic gynaecologic oncology exist, and admission to a robotic course requires a surgical background: an MS in obstetrics and gynaecology or in general surgery under Indian rules, with at least some operative experience such as caesarean section, so that the trainee understands the basics of surgery. Her full answers on training and fellowships are in the Live Discussion from this masterclass.

The future of robotic surgery: da Vinci 5, AI and single-port surgery

Dr. Dahiya sees a long road still ahead. Next-generation platforms such as the da Vinci 5 are arriving, and AI integration is becoming more important. Single-port robotic surgery, in which the operation is performed through one small incision, usually at the navel, is being done worldwide for simple operations such as hysterectomy and cholecystectomy (gallbladder removal). She noted that it was not yet being performed in India at the time of the session. She has watched a surgeon in South Korea remove an ovarian cyst through a single 2 centimetre umbilical port, and single-port surgery is also performed in the USA. In her assessment it is suitable only for simple operations with a light specimen: a small uterus, a small ovarian cyst or a gallbladder.

Four principles for robotic gynaecologic oncology

Dr. Dahiya's closing message reduces the subject to four commitments: careful patient selection; strict containment, meaning no spillage, liberal use of specimen retrieval bags and early conversion whenever contamination is suspected; surgical mastery; and continued evidence-based practice. Within those limits, she concludes, robotic surgery improves the quality of surgery and brings the benefits of minimally invasive surgery to women with gynaecological cancer without compromising oncological outcomes.

For the wider clinical picture of these cancers, including screening and early symptoms, see the overview of gynaecological cancers from Dr. Punyashree R M's masterclass. Gynaecological cancer care sits within the site's oncology and obstetrics and gynaecology specialties.